Biotech | December 11, 2021
Alembic acquires stake in RIGlmmune
The company is focused on the development of novel treatments for RNA viruses
The company is focused on the development of novel treatments for RNA viruses
Results from the ongoing vodobatinib clinical study are being presented for the second consecutive year at the ASH annual meeting, underlining the promising potential of the drug for the treatment of heavily pre-treated CML
Under this scheme, the company will make a committed investment in plant and machinery, get incentives on incremental sales of pharmaceutical products
The setting up of these 8 plants will lead to a total committed investment of Rs. 260.40 crore
Brii Bio announces amubarvimab/romlusevimab combination received approval from NMPA
Both companies will combine their expertise to channel real-world evidence toward ground-breaking new treatments in rare diseases
Saroglitazar Mg is an investigational compound in the USA, and is yet to be approved by the U.S. Food & Drug Administration (USFDA) or European Medicines Agency (EMA)
The interim results of Phase 3 clinical trials conducted by CanSinoBIO demonstrated that Convidecia has an efficacy of 95.47% at preventing severe disease 14 days after single-dose vaccination.
Lupin Diagnostics will provide a comprehensive range of diagnostic tests. These include molecular diagnostics, cytogenetics, flow cytometry, microbiology, serology, histopathology and cytology, haematology, immunology, amongst others.
An MoU was signed between B Medical Systems and Gujarat government recently
Subscribe To Our Newsletter & Stay Updated
